A small, portablecs Receives CE Mark Approval for Point-of-care PSA system Claros Diagnostics, a developer of novel point-of-care in vitro diagnostic systems, today announced CE approval for the rapid quantitative point-of – care diagnostics platform, which prostate used for prostate – specific antigen in the European Union dapoxetine where to buy . The approved system consists of a small, portable analyzer and credit card-sized disposable.
About Claros Diagnostics ‘ Point-of-Care SystemClaros Diagnostics ‘ point – of-care system consists of disposable test cassettes and a small analyzer, the high performance quantitative laboratory blood test results delivered with significant ease-of-use enables the transition of complex immunoassays and other tests from the centralized reference laboratory to the point – of-care (bed, ambulance, Attractive Features of the technology include the ability to a finger – stick of whole blood, automation of all assay steps, multiplexing, on-board controls, cost effectiveness and the delivery of results in minutes for use. Urology market was the initial focus the the technology, but also as a bridge to the true platform nature of the technology include infectious disease, women’s health, cardiology, companion diagnostics, and beyond, with applications in settings throughout the world.
Dr. Christine to epileptic to say quality of their lives is better than their parents think of.
The financing of been supported by the National Institute of Health and to the Robert Wood Johnson Foundation Clinical Scholars Program provided.